A new high potency active pharmaceutical ingredients unit is today being opened by Medichem at its Malta plant in Hal Far.

The company said in a statement that with this new offering it wants to consolidate its presence in the generic pharmaceutical industry.

“Our expansion to HPAI field will allow Medichem to offer a broader product portfolio to our customers. Today, 25 per cent of new drugs in development are highly potent, and we expect this tendency to keep growing”, CEO Ervin Veszprémi said.

Malta’s unique patent situation allows Medichem to develop and produce HPAI in advance of patent expiry.

Sign up to our free newsletters

Get the best updates straight to your inbox:
Please select at least one mailing list.

You can unsubscribe at any time by clicking the link in the footer of our emails. We use Mailchimp as our marketing platform. By subscribing, you acknowledge that your information will be transferred to Mailchimp for processing.